Loading
Discovered the BCR-ABL kinase activity that imatinib blocks and now hunts for new prostate cancer targets.
Owen Witte is University Professor and Founding Director Emeritus of the Broad Stem Cell Research Center at UCLA, within the UCLA Jonsson Comprehensive Cancer Center. A molecular biologist specialising in prostate cancer biology and kinase signalling, he identified the tyrosine kinase activity of the BCR-ABL oncoprotein, the basis of imatinib. His papers include the Cell report that an alteration of the human c-abl protein in K562 leukaemia cells unmasks associated tyrosine kinase activity and a Science study reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. His laboratory now defines prostate cancer lineage plasticity and hunts for immunotherapy targets such as PSCA and STEAP1, alongside PSMA and the androgen receptor.
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Imatinib.
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, Prostate cancer.
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, Prostate cancer.
Shares STEAP1, Prostate cancer.
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Imatinib.
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Androgen receptor, Prostate cancer.
Shares Brian Druker, Imatinib.
Shares PSMA, Prostate cancer.